The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COSTEM 2022 | The impact of CAR-T therapy in the second-line setting in lymphoma
Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center, New York, NY, describes the effect of introducing CAR-T therapies such as axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) as second-line therapies in lymphomas such as diffuse large B-cell lymphoma (DLBCL). Despite negative results from the BELINDA trial (NCT03570892), the ZUMA-7 (NCT03391466) and TRANSFORM trials (NCT03575351) have enabled the approval of CAR-Ts into the armamentarium. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
